<DOC>
	<DOCNO>NCT01235754</DOCNO>
	<brief_summary>The objective study evaluate persistence benefit LibiGel ( testosterone gel ) 300 mcg/day compare placebo gel 12 week post-treatment period Hypoactive Sexual Desire Disorder ( HSDD ) surgically menopausal woman .</brief_summary>
	<brief_title>Extension Study Assess Persistence Benefit LibiGel Treatment Hypoactive Sexual Desire Disorder ( HSDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>must complete minimum 22 week 24week TESTW006 TESTW008 clinical trial Any condition ( include change sexual relationship history ) would make subject unsuitable participation trial opinion Investigator</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>testosterone</keyword>
	<keyword>hypoactive sexual desire disorder</keyword>
	<keyword>menopause</keyword>
</DOC>